CD47 and cancer: The first report demonstrating that disrupting the CD47–SIRPα interaction in lung cancer had anti-tumor effects was that by Weiskopf and colleagues, who showed that CD47 blockade with a mAb in SCLC cell lines and patient-derived xenografts enhanced cancer cell phagocytosis by macrophages [218].